Use of high-throughput DNA microarrays to identify biomarkers for bladder cancer

Clinical Chemistry

Volumn 49, Issue 1, 2003, Pages 23-31

  Sánchez Carbayo, Marta ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; DNA; TUMOR MARKER;

BLADDER CANCER; CANCER STAGING; CLINICAL LABORATORY; DNA FINGERPRINTING; DNA MICROARRAY; GENE CLUSTER; GENE EXPRESSION REGULATION; HEALTH CARE QUALITY; HIGH THROUGHPUT DNA MICROARRAY; HUMAN; MOLECULAR MODEL; PREDICTION; PROGNOSIS; REVIEW; STANDARDIZATION; TECHNOLOGY; TISSUE SPECIFICITY; TREATMENT OUTCOME;

GENE EXPRESSION PROFILING; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 0037232996     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/49.1.23     Document Type: Review

References (64)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin 1999;49:8-31.
2. Reuter VE, Melamed MR. The lower urinary tract. In: Sternberg SS, ed. Diagnostic surgical pathology. New York: Raven Press, 1989: 1355-92.
3. de Vere White RW, Stapp E. Predicting prognosis in patients with superficial bladder tumors. Oncology 1998;12:1717-23.
4. Neiman PE, Hartwell LH. Malignant instability. Workshop on Genetic Instability and its Role in Carcinogenesis sponsored by the Programs in Molecular Medicine of the Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, WA, U S A, January 11-12, 1991. New Biol 1991;3:347-51.
5. Balazs M, Carroll P, Kerschmann R, Sauter G, aldman FM. Frequent homozygous deletion of cyclin-dependent kinase inhibitor 2 (MTS1, p16) in superficial bladder cancer detected by fluorescence in situ hybridization. Genes Chromosomes Cancer 1997;19:84-9.
6. Cote RJ, Dunn MD, Chatterjee SJ, Stein JP, Shi SR, Tran QC, et al. Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res 1998;58:1090-4.
7. Knowles MA. What we could do now: molecular pathology of bladder cancer. Mol Pathol 2001;54:215-21.
8. Wiener HG, Vooijs GP, van't Hof-Grootenboer B. Accuracy of urinary cytology in the diagnosis of primary and recurrent bladder cancer. Acta Cytol 1993;37:163-9.
9. Thomas L, Leyh H, Marberger M, Bombardieri E, Bassi P, Pagano F, et al. Multicenter trial of the quantitative BTA TRAK assay in the detection of bladder cancer. Clin Chem 1999;45:472-7.
10. Schmetter BS, Habicht KK, Lamm DL, Morales A, Bander NH, Grossman HB, et al. A multicenter trial evaluation of the fibrin/ fibrinogen degradation products marcador for detection and monitoring of bladder cancer. J Urol 1997;158:801-5.
11. Soloway MS, Briggman V, Carpinito GA, Chodak GW, Church PA, et al. Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J Urol 1996;156:363-7.
12. Mian C, Pycha A, Wiener H, Haitel A, Lodde M, Marberger M. Immunocyt: a new tool for detecting transitional cell cancer of the urinary tract. J Urol 1999;161:1486-9.
13. Dalbagni G, Han W, Zhang ZF, Cordon-Cardo C, Saigo P, Fair WR, et al. Evaluation of the telomeric repeat amplification protocol (TRAP) assay for telomerase as a diagnostic modality in recurrent bladder cancer. Clin Cancer Res 1997;3:1593-8.
14. Pham HT, Block NL, Lokeshwar VB. Tumor-derived hyaluronidase: a diagnostic urine marker for high-grade bladder cancer. Cancer Res 1997;57:778-83.
15. van der Poel HG, Witjes JA, van Stratum P, Boon ME, Debruyne FM, Schalken JA. Quanticyt: karyometric analysis of bladder washing for patients with superficial bladder cancer. Urology 1996;48:357-64.
16. Sanchez-Carbayo M, Herrero E, Megias J, Mira A, Espasa A, Chinchilla V, Soria F. Initial evaluation of the diagnostic performance of the new urinary bladder cancer antigen test as a tumor marker for transitional cell carcinoma of the bladder. J Urol 1999;161:1110-5.
17. Schneider A, Borgnat S, Lang H, Regine O, Lindner V, Kassem M, et al. Evaluation of microsatellite analysis in urine sediment for diagnosis of bladder cancer. Cancer Res 2000;60:4617-22.
18. Sanchez-Carbayo M, Espasa A, Chinchilla V, Herrero E, Megias J, Mira A, et al. New electrochemiluminescent immunoassay for the determination of CYFRA 21-1: analytical evaluation and clinical diagnostic performance in urine samples of patients with bladder cancer. Clin Chem 1999;45:1944-53.
19. Konety BR, Nguyen TS, Dhir R, Day RS, Becich MJ, Stadler WM, et al. Detection of bladder cancer using a novel nuclear matrix protein, BLCA-4. Clin Cancer Res 2000;6:2618-25.
20. Sanchez-Carbayo M, Urrutia M, Gonzalez de Buitrago JM, Navajo JA. Evaluation of two new urinary tumor markers: bladder tumor fibronectin and cytokeratin 18 for the diagnosis of bladder cancer. Clin Cancer Res 2000;6:3585-94.
21. Bubendorf L, Grilli B, Sauter G, Mihatsch MJ, Gasser TC, et al. Multiprobe FISH for enhanced detection of bladder cancer in voided urine specimens and bladder washings. Am J Clin Pathol 2001;116:79-86.
22. Sanchez-Carbayo M, Urrutia M, Gonzalez de Buitrago JM, Navajo JA. Utility of serial urinary tumor markers to individualize intervals between cystoscopies in the monitoring of patients with bladder carcinoma. Cancer 2001;92:2820-8.
23. Lotan Y, Roehrborn CG. Cost-effectiveness of a modified care protocol substituting bladder tumor markers for cystoscopy for the followup of patients with transitional cell carcinoma of the bladder: a decision analytical approach. J Urol 2002;167:75-9.
24. Burchardt M, Burchardt T, Shabsigh A, De La Taille A, Benson MC, Sawczuk I. Current concepts in biomarker technology for bladder cancers. Clin Chem 2000;46:595-605.
25. Buchumensky V, Klein A, Zemer R, Kessler OJ, Zimlichman S, Nissenkorn I. Cytokeratin 20: a new marker for early detection of bladder cell carcinoma? J Urol 1998;160:1971-4.
26. Konety BR, Nguyen TS, Brenes G, Sholder A, Lewis N, Bastacky S, et al. Clinical usefulness of the novel marker BLCA-4 for the detection of bladder cancer. J Urol 2000;164:634-9.
27. Smith SD, Wheeler MA, Plescia J, Colberg JW, Weiss RM, Altieri DC. Urine detection of survivin and diagnosis of bladder cancer. JAMA 2001;285:324-8.
28. Mohammed SI, Knapp DW, Bostwick DG, Foster RS, Khan KN, Masferrer JL, et al. Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder. Cancer Res 1999;59:5647-50.
29. Stoeber K, Halsall I, Freeman A, Swinn R, Doble A, Morris L, et al. Immunoassay for urothelial cancers that detects DNA replication protein Mcm5 in urine. Lancet 1999;354:1524-5.
30. Jankevicius F, Shibayama T, Decken K, Bojar H, Gerharz CD, Ebert T, et al. Dual-parameter immunoflow cytometry in diagnosis and followup of patients with bladder cancer. Eur Urol 1998;34:492-9.
31. Liotta L, Petricoin E. Molecular profiling of human cancer [Review]. Nat Rev Genet 2000;1:48-56.
32. Liang P, Pardee AB. Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction. Science 1992; 257:967-71.
33. Velculescu VE, Zhang L, Vogelstein B, Kinzler KW. Serial analysis of gene expression. Science 1995;270:484-7.
34. Haab BB, Dunham MJ, Brown PO. Protein microarrays for highly parallel detection and quantitation of specific proteins and antibodies in complex solutions. Genome Biol 2001;2:1-4.
35. Pandey A, Mann M. Proteomics to study genes and genomes. Nature 2000;405:837-46.
36. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, et al. Initial sequencing and analysis of the human genome. International Human Genome Sequencing Consortium. Nature 2001;409:860-921.
37. Venter JC. Remarks at the Human Genome announcement. Funct Integr Genomics 2000;1:154-5.
38. Duggan DJ, Bittner M, Chen Y, Meltzer P, Trent JM. Expression profiling using cDNA microarrays. Nat Genet 1999;21:10-4.
39. Hacia JG, Collins FS. Mutational analysis using oligonucleotide microarrays. J Med Genet 1999;36:730-6.
40. Iyer VR, Horak CE, Scafe CS, Botstein D, Snyder M, Brown PO. Genomic binding-sites of the yeast cell-Cycle transcription factors SBF and MBF. Nature 2001;25;409:533-8.
41. Pinkel D, Segraves R, Sudar D, Clark S, Poole I, Kowbel D, et al. High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat Genet 1998;20:207-11.
42. Hoos A, Urist MJ, Stojadinovic A, Mastorides S, Dudas ME, Leung D, et al. Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors. Am J Pathol 2001;158:1245-51.
43. Rubin M, Zhou M, Dhanasekaran SM, Varambally S, Barrette TR, Sanda MG, et al. α-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA 2002;287:1662-70.
44. Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M, et al. Phases of marker development for early detection of cancer. J Natl Cancer Inst 2001;93:1054-61.
45. Chert CC, Shieh B, Jin YT, Liau YE, Huang CH, Liou JT, et al. Microarray profiling of gene expression patterns in bladder tumor cells treated with genistein. J Biomed Sci 2001;8:214-22.
46. Maxwell SA, Davies GE. Differential gene expression in p53-mediated apoptosis-resistant vs. apoptosis-sensitive tumor cell lines. Proc Natl Acad Sci U S A 2000;97:13009-14.
47. Sanchez-Carbayo M, Socci N, Charytonowicz E, Lu M, Prystosky M, Childs G, et al. Molecular profiling of bladder cancer using cDNA microarrays: defining histogenesis and biological phenotypes. Cancer Res 2002;62:in press.
48. Dangles V, Lazar V, Validire P, Richon S, Wertheimer M, Laville V, et al. Gene expression profiles of bladder cancers: evidence for a striking effect of in vitro cell models on gene patterns. Br J Cancer 2002;86:1283-9.
49. Thykjaer T, Workman C, Kruhoffer M, Demtroder K, Wolf H, Andersen LD, et al. Identification of gene expression patterns in superficial and invasive human bladder cancer. Cancer Res 2001;61:2492-9.
50. Sanchez-Carbayo M, Belbin T, Socci N, Charytonowicz E, Harris T, Prystowsky M, et al. Expression profiling of bladder tumors using cDNA microarrays. Clin Chem 2002;48(Suppl 6):A26.
51. Lu M-L, Wikman F, Orntoft TF, Charytonowicz E, Rabbani F, Zhang Z, et al. Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods. Clin Cancer Res 2002;8:171-9.
52. Richter J, Wagner U, Kononen J, Fijan A, Bruderer J, Schmid U, et al. High-throughput tissue microarray analysis of cyctin E gene amplification and overexpression in urinary bladder cancer. Am J Pathol 2000;157:787-94.
53. Fakhari M, Pullirsch D, Abraham D, Paya K, Hofbauer R, Ḣolzfeind P, et al. Selective upregulation of vascular endothelial growth factor receptors neuropilin-1 and -2 in human neuroblastoma. Cancer 2002;94:258-63.
54. Nocito A, Bubendorf L, Maria Tinner E, Suess K, Wagner U, Forster T, et al. Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade. J Pathol 2001;194:349-57.
55. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-7.
56. Wikman FP, Lu ML, Thykjaer T, Olesen SH, Andersen LD, Cordon-Cardo C, et al. Evaluation of the performance of a p53 sequencing microarray chip using 140 previously sequenced bladder tumor samples. Clin Chem 2000;46:1555-61.
57. Primdahl H, Wikman FP, von der Maase H, Zhou XG, Wolf H, Orntoft TF. Allelic imbalances in human bladder cancer: genome-wide detection with high-density single-nucleotide polymorphism arrays. J Natl Cancer Inst 2002;94:216-23.
58. Granjeaud S, Bertucci F, Jordan BR. Expression profiling: DNA arrays in many guises. Bioessays 1999;21:781-90.
59. Cheung VG, Morley M, Aguilar F, Massimi A, Kucherlapati R, Childs G. Making and reading microarrays. Nat Genet 1999;21: 15-9.
60. Stears RL, Getts RC, Gullans SR. A novel, sensitive detection system for high-density microarrays using dendrimer technology. Physiol Genomics 2000;3:93-9.
61. Wang E, Miller LD, Ohnmacht GA, Liu ET, Marincola FM. High-fidelity mRNA amplification for gene profiling. Nat Biotechnol 2000;18:457-9.
62. Eberwine J, Yeh H, Miyashiro K, Cao Y, Nair S, Finnell R, et al. Analysis of gene expression in single live neurons. Proc Natl Acad Sci U S A 1992;89:3010-4.
63. Klimecki WT, Futscher BW, Dalton WS. Effects of ethanol and paraformaldehyde on RNA yield and quality. Biotechniques 1994; 16:1021-3.
64. Specht K, Richter T, Muller U, Walch A, Werner M, Hofler H. Quantitative gene expression analysis in microdissected archival formalin-fixed and paraffin-embedded tumor tissue. Am J Pathol 2001;158:419-29.